Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Sanofi
Company Monitoring Page for Sanofi
latest headlines for company on cafepharma
Mixed court decisions for Novartis in DC and Sanofi, Novo Nordisk in NJ further complicate whose interpretation of 340B is correct
Endpoints
Mon, 11/8/21 - 10:46 am
Tags:
legal
,
drug discounts
,
340B
,
Medicare
,
Sanofi
,
Novartis
,
Novo Nordisk
Judge rules HHS' letter enforcing 340B discounts was 'arbitrary'
Beckers Hospital Review
Tue, 11/2/21 - 11:51 pm
Tags:
HHS
,
drug pricing
,
340B
,
AstraZeneca
,
Eli Lilly
,
Novo Nordisk
,
Sanofi
,
United Therapeutics
Sanofi's €10B sales target for Dupixent? The 'megabrand' is more than halfway there, exec says
Fierce Pharma
Thu, 10/28/21 - 10:57 am
Tags:
Sanofi
,
Dupixent
,
earnings
Sanofi hit by filing delays for key drugs, drops an early Sangamo thalassemia asset
Fierce Biotech
Thu, 10/28/21 - 10:40 am
Tags:
Sanofi
,
earnings
,
fitusiran
,
Sangamo
,
breast cancer
Sanofi, Regeneron gear up for new Dupixent filing after clearing second PhIII for eosinophilic esophagitis
Endpoints
Mon, 10/25/21 - 10:48 am
Tags:
Sanofi
,
Regeneron
,
Dupixent
,
eosinophilic esophagitis
,
clinical trials
Dupixent scores a first in rare skin disease prurigo nodularis
Pharmaforum
Fri, 10/22/21 - 11:22 am
Tags:
Sanofi
,
Regeneron
,
Dupixent
,
prurigo nodularis
ReCode Therapeutics gets $80M to deliver on new RNA therapies for the lungs
MedCity News
Thu, 10/21/21 - 11:26 pm
Tags:
ReCode Therapeutics
,
funding
,
Pfizer
,
Sanofi
,
lipid nanoparticles
Actemra shortage spills over to include Sanofi’s rival Kevzara
Pharmaforum
Tue, 10/12/21 - 11:45 pm
Tags:
Roche
,
Actemra
,
Sanofi
,
Kevzara
,
drug shortages
Regeneron Could Have a Big Catalyst Coming in 2022
Motley Fool
Sat, 10/9/21 - 11:11 pm
Tags:
Regeneron
,
Libtayo
,
cervical cancer
,
FDA
,
Sanofi
Sanofi, GSK, Pfizer and Boehringer must face Zantac class-action lawsuits, court rules
Fierce Pharma
Fri, 10/8/21 - 11:00 am
Tags:
GSK
,
Sanofi
,
Pfizer
,
Boehringer Ingelheim
,
legal
,
class action lawsuits
,
Zantac
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo approach
Fierce Biotech
Fri, 10/8/21 - 10:34 am
Tags:
Sanofi
,
Mirati Therapeutics
,
adagrasib
,
non-small cell lung cancer
Denali Moving Forward with Sanofi-Partnered ALS Candidate
BioSpace
Thu, 10/7/21 - 12:17 pm
Tags:
Denali Therapeutics
,
Sanofi
,
ALS
,
DNL343
,
clinical trials
Sanofi, Moderna beef up the case for giving flu, Covid-19 vaccines to elderly in the same visit
Endpoints
Thu, 10/7/21 - 11:20 am
Tags:
Sanofi
,
Moderna Therapeutics
,
clinical trials
,
elderly
,
vaccines
,
COVID-19
,
Flu
Biopharma needs a biggie to avoid a down deal year
EP Vantage
Thu, 10/7/21 - 11:07 am
Tags:
M&A
,
Merck
,
Acceleron
,
Sanofi
,
Translate Bio
,
Amgen
,
Teneobio
,
Pfizer
,
Trillium
,
Perrigo
,
HRA Pharma
Is the cancer immunotherapy market up for disruption as AstraZeneca, Regeneron-Sanofi, cheaper Chinese offerings line up?
Fierce Pharma
Sun, 10/3/21 - 08:27 pm
Tags:
cancer
,
oncology
,
cancer immunotherapy
,
Merck
,
AstraZeneca
,
Regeneron
,
Sanofi
Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema
Pharmaforum
Fri, 10/1/21 - 10:48 am
Tags:
Sanofi
,
eczema
,
M&A
,
Kymab
,
KY1005
,
clinical trials
Sanofi calls it quits on mRNA Covid-19 shots, scrapping vaccine from $3.2B Translate Bio buyout
Endpoints
Tue, 09/28/21 - 11:21 am
Tags:
Sanofi
,
MRNA
,
COVID-19
,
vaccines
,
Translate Bio
Oncology the focus for big pharma catalysts
EP Vantage
Tue, 09/28/21 - 11:19 am
Tags:
Big Pharma
,
cancer
,
oncology
,
Merck
,
Keytruda
,
AbbVie
,
Vraylar
,
Gilead Sciences
,
Trodelvy
,
Sanofi
,
Sarclisa
,
Novartis
,
ligelizumab
HHS lines up Novartis, Lilly, AstraZeneca and 3 other drugmakers for fines due to drug discount violations
Endpoints
Fri, 09/24/21 - 12:00 pm
Tags:
HHS
,
340B
,
discounts
,
Novartis
,
Eli Lilly
,
AstraZeneca
,
Novo Nordisk
,
Sanofi
,
United Therapeutics
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
Pharmaforum
Mon, 09/20/21 - 11:07 am
Tags:
Sanofi
,
Regeneron
,
Libtayo
,
ESMO
,
non-small cell lung cancer
,
Merck
,
Keytruda
Pages
« first
‹ previous
…
17
18
19
20
21
22
23
24
25
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
cafepharma is a: rock, tree, site
*
Fill in the blank.